Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
Cybin IRL Limited
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- EXTEND
- status
- ENROLLING_BY_INVITATION
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 468
- sponsor
- Cybin IRL Limited
- conditions
- Major Depressive Disorder
- interventions
- DRUG: CYB003
- start date
- 2025-07-18
- start date type
- ACTUAL
- primary completion date
- 2028-06-06
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT06605105
- Published
- Sep 20, 2024
- Updated
- Sep 25, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT06605105
- Categories
- Major Depressive Disorder
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials